A leading Coronavirus vaccine candidate developed by Pfizer and BioNTech will be submitted for regulatory approval within days, the companies announced today.
This was finalised after it was suggested that the drugs are now working more efficiently than ever.
The U.S. pharma giant and its German partner said their “Phase 3” trial has now completed, and the vaccine is now 95 percent effective at preventing symptomatic Covid-19, which was on 90 per cent last week.
Currently there have been no serious side effects among the 41,135 adults who received two doses; common reactions include fatigue and headache which was among 3 percent.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” Dr. Albert Bourla, Pfizer chairman and CEO, said in the statement. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”
Experts have urged caution though, but this news still has arrived as a glimmer of hope in a bleak year.